公开(公告)号：US20170130248A1

公开(公告)日：2017-05-11

申请号：US15312627

申请日：2015-04-28

Applicant: Evonik Degussa GmbH

Inventor： LIV REINECKE ,  STEFFEN SCHAFFER ,  KATRIN GRAMMANN ,  MAIK OLFERT ,  NICOLE DECKER ,  NILS ARTO ,  HANS-GEORG HENNEMANN

IPC: C12P13/00 ,  C12N9/88 ,  C12N9/00 ,  C12N9/10

CPC classification number: C12P13/005 ,  C12N9/1014 ,  C12N9/1029 ,  C12N9/88 ,  C12N9/93 ,  C12P13/02 ,  C12Y201/02001 ,  C12Y203/01065 ,  C12Y401/02005 ,  C12Y602/01 ,  C12Y602/01001

Abstract: The present invention relates to a cell for producing acyl glycinates wherein the cell is genetically modified to comprise at least a first genetic mutation that increases the expression relative to the wild type cell of an amino acid-N-acyl-transferase, at least a second genetic mutation that increases the expression relative to the wild type cell of an acyl-CoA synthetase, and at least a third genetic mutation that decreases the expression relative to the wild type cell of at least one enzyme selected from the group consisting of an enzyme of the glycine cleavage system, glycine hydroxymethyltransferase (GlyA) and threonine aldolase (LtaE).

公开(公告)号：US20180016546A1

公开(公告)日：2018-01-18

申请号：US15545513

申请日：2016-01-27

Applicant: Danmarks Tekniske Universitet

Inventor： Hemanshu Mundhada ,  Alex Toftgaard Nielsen

IPC: C12N1/36 ,  C12N9/88 ,  C12P13/06 ,  C12N9/10 ,  C12N9/04 ,  C07K14/32 ,  C12N9/16

CPC classification number: C12N1/36 ,  C07K14/245 ,  C07K14/32 ,  C12N1/20 ,  C12N9/0006 ,  C12N9/1014 ,  C12N9/1096 ,  C12N9/1205 ,  C12N9/1217 ,  C12N9/1247 ,  C12N9/16 ,  C12N9/88 ,  C12N9/90 ,  C12N9/93 ,  C12N15/01 ,  C12N15/52 ,  C12P13/001 ,  C12P13/06 ,  C12P13/12 ,  C12P13/22 ,  C12P17/165 ,  C12P17/167 ,  C12Y101/01003 ,  C12Y101/01095 ,  C12Y201/02001 ,  C12Y206/01052 ,  C12Y207/02003 ,  C12Y301/03003 ,  C12Y403/01017

Abstract: The present invention generally relates to the microbiological industry, and specifically to the production of L-serine using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.

公开(公告)号：US20150030854A1

公开(公告)日：2015-01-29

申请号：US14182031

申请日：2014-02-17

Applicant: SNU R&DB FOUNDATION

Inventor： Jong Hoon Chung ,  Shambhavi Pandey ,  Pankaj Garg ,  Pill Hoon Choung

IPC: A61K47/48 ,  C12N15/113 ,  A61K48/00

CPC classification number: A61K48/0075 ,  A61K47/551 ,  A61K47/59 ,  A61K47/6921 ,  A61K48/0041 ,  C12N15/111 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/351 ,  C12N2320/32 ,  C12Y201/02001 ,  Y10T428/2982

Abstract: The present invention relates to a vitamin B6-coupled poly(ester amine) (VBPEA) as a gene carrier and a method for preparing the gene carrier. Moreover, the present invention relates to a gene delivery complex comprising a therapeutic gene coupled to the gene carrier and a pharmaceutical formulation for gene therapy, which comprises the gene delivery complex as an active ingredient. In addition, the present invention relates to gene therapy utilizing the gene carrier, the gene delivery complex or the pharmaceutical formulation. The VBPEA of the invention has a significantly high gene delivery rate compared to existing gene carriers and a complex of the VBPEA with DNA has little or no cytotoxicity and shows a very high in vivo transfection efficiency. In addition, a complex of the VBPEA with siRNA shows high gene silencing efficiency and can induce a high rate of cell death and the inhibition of cell proliferation in cancer cells, suggesting that it can be used for anticancer gene therapy. Thus, the gene carrier VBPEA of the invention can be used as an experimental gene carrier and can also be widely used in gene therapy against various diseases depending on the kind of therapeutic gene.

Abstract translation: 本发明涉及作为基因载体的维生素B6-偶联聚（酯胺）（VBPEA）和制备该基因载体的方法。 此外，本发明涉及包含与基因载体偶联的治疗基因和用于基因治疗的药物制剂的基因递送复合物，其包含基因递送复合物作为活性成分。 此外，本发明涉及利用基因载体，基因递送复合物或药物制剂的基因治疗。 与现有基因载体相比，本发明的VBPEA具有显着高的基因传递速率，并且VBPEA与DNA的复合物几乎没有或没有细胞毒性，并且显示出非常高的体内转染效率。 此外，VBPEA与siRNA的复合物显示出高的基因沉默效率，并且可以诱导高细胞死亡率和癌细胞中细胞增殖的抑制，这表明其可用于抗癌基因治疗。 因此，本发明的基因载体VBPEA可以用作实验基因载体，也可以根据治疗基因的种类广泛用于各种疾病的基因治疗。

公开(公告)号：US20090170171A1

公开(公告)日：2009-07-02

申请号：US11942873

申请日：2007-11-20

Applicant: Shinji Kuroda ,  Hiroyuki Nozaki ,  Kunihiko Watanabe ,  Kenzo Yokozeki ,  Yuki Imabayashi

Inventor： Shinji Kuroda ,  Hiroyuki Nozaki ,  Kunihiko Watanabe ,  Kenzo Yokozeki ,  Yuki Imabayashi

IPC: C12P13/06 ,  C12N9/00 ,  C07H21/00 ,  C12N1/00

CPC classification number: C12N9/1014 ,  C12P13/06 ,  C12Y201/02001

Abstract: The present invention provides a new method for producing serine derivatives and their optically-activated derivatives in a convenient manner. In the presence of an enzyme, an L-α-amino acid of formula (I): (in the formula (I), R1 is a hydrocarbon group) is reacted with an aldehyde of formula (II): (in the formula (II), R2 is a hydrocarbon) to produce an L-serine derivative of formula (III).

Abstract translation: 本发明提供了以方便的方式制备丝氨酸衍生物及其光活性衍生物的新方法。 在酶的存在下，式（I）:(式（I）中的R 1为烃基）的式（I）的L-α-氨基酸与式（II）的醛反应：（在式 II），R 2为烃），得到式（III）的L-丝氨酸衍生物。

公开(公告)号：US20180265905A1

公开(公告)日：2018-09-20

申请号：US15921442

申请日：2018-03-14

Applicant: Timothy A. Wencewicz ,  Jason E. Schaffer ,  Margaret R. Reck

Inventor： Timothy A. Wencewicz ,  Jason E. Schaffer ,  Margaret R. Reck

IPC: C12P17/02

CPC classification number: C12P17/02 ,  C12Y201/02001 ,  C12Y207/08007 ,  C12Y401/01001 ,  C12Y401/02005

Abstract: Methods of producing peptide beta-lactones and beta-hydroxy acids are disclosed that include contacting a beta-hydroxy-alpha-amino acid, an aryl carrier protein (ObiD), and ATP with a non-ribosomal protein synthetase. A continuous flow reactor is disclosed that includes an elongate conduit with at least one region that includes a first region with a non-ribosomal protein synthetase immobilized to a substrate. The non-ribosomal protein synthetase of the continuous flow reactor is configured to contact a flow of a reaction mixture that includes a beta-hydroxy-alpha-amino acid and an aryl carrier protein. The non-ribosomal protein synthetase is further configured to release a peptide beta-lactone into the flow of the reaction mixture.

公开(公告)号：US09872925B2

公开(公告)日：2018-01-23

申请号：US14182031

申请日：2014-02-17

Applicant: SNU R&DB FOUNDATION

Inventor： Jong Hoon Chung ,  Shambhavi Pandey ,  Pankaj Garg ,  Pill Hoon Choung

IPC: A61K48/00 ,  C12N15/11 ,  C12N15/113 ,  A61K47/55 ,  A61K47/59 ,  A61K47/69

CPC classification number: A61K48/0075 ,  A61K47/551 ,  A61K47/59 ,  A61K47/6921 ,  A61K48/0041 ,  C12N15/111 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/351 ,  C12N2320/32 ,  C12Y201/02001 ,  Y10T428/2982

Abstract: The present invention relates to a vitamin B6-coupled poly(ester amine) (VBPEA) as a gene carrier and a method for preparing the gene carrier. Moreover, the present invention relates to a gene delivery complex comprising a therapeutic gene coupled to the gene carrier and a pharmaceutical formulation for gene therapy, which comprises the gene delivery complex as an active ingredient. In addition, the present invention relates to gene therapy utilizing the gene carrier, the gene delivery complex or the pharmaceutical formulation. The VBPEA of the invention has a significantly high gene delivery rate compared to existing gene carriers and a complex of the VBPEA with DNA has little or no cytotoxicity and shows a very high in vivo transfection efficiency. In addition, a complex of the VBPEA with siRNA shows high gene silencing efficiency and can induce a high rate of cell death and the inhibition of cell proliferation in cancer cells, suggesting that it can be used for anticancer gene therapy. Thus, the gene carrier VBPEA of the invention can be used as an experimental gene carrier and can also be widely used in gene therapy against various diseases depending on the kind of therapeutic gene.

公开(公告)号：US20160160186A1

公开(公告)日：2016-06-09

申请号：US14605320

申请日：2015-01-26

Applicant: SynPhaGen LLC.

Inventor： Todd Bernard PARSLEY ,  Christian Furlan FREGUIA

IPC: C12N7/00 ,  C02F3/34 ,  C12N15/63 ,  A01N63/00 ,  C12N15/113

CPC classification number: C02F3/34 ,  A01N63/02 ,  A61K38/2066 ,  A61K38/45 ,  A61K38/482 ,  A61K48/005 ,  C12N7/00 ,  C12N15/111 ,  C12N15/113 ,  C12N15/70 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/32 ,  C12N2330/50 ,  C12N2795/00021 ,  C12N2795/00031 ,  C12N2795/00032 ,  C12N2795/00043 ,  C12N2795/14143 ,  C12N2820/55 ,  C12Y201/02001 ,  C12Y203/02013

Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.

Abstract translation: 公开了噬菌体颗粒的组合物。 噬菌体颗粒是非复制型的，并且包括能够在靶细菌中表达的至少一种异源核酸序列。 表达的异源核酸序列对靶细菌是非致死的。

公开(公告)号：WO2006123745A1

公开(公告)日：2006-11-23

申请号：PCT/JP2006/309949

申请日：2006-05-18

Applicant: 味の素株式会社 ,  黒田 愼二 ,  野崎 博之 ,  渡部 乙比古 ,  横関 健三 ,  今林 由希

Inventor： 黒田 愼二 ,  野崎 博之 ,  渡部 乙比古 ,  横関 健三 ,  今林 由希

IPC: C12N15/09 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/10 ,  C12P13/04

CPC classification number: C12N9/1014 ,  C12P13/06 ,  C12Y201/02001

Abstract: 　簡便な手法によるセリン誘導体およびその光学活性体を生成する新たな方法を提供する。所定の酵素の存在下で、 （式（Ｉ）において、Ｒ 1 は、所定の炭化水素基） に示されるＬ－α－アミノ酸と、下記式（ＩＩ）： （式（ＩＩ）においてＲ 2 は所定の炭化水素基） に示されるアルデヒドとを反応させて、式（ＩＩＩ）： に示されるＬ－セリン誘導体を生成させる。

Abstract translation: 公开了通过简单的方法制备丝氨酸衍生物和光学活性形式的新方法。 该方法包括使由式（I）表示的La-氨基酸（其中R 1表示特定烃基）与由式（II）表示的醛反应的步骤：（其中 R 2表示特定的烃基），以产生由式（III）表示的L-丝氨酸衍生物。

公开(公告)号：WO2015002604A1

公开(公告)日：2015-01-08

申请号：PCT/SE2014/050848

申请日：2014-07-03

Applicant: OXTHERA INTELLECTUAL PROPERTY AB

Inventor： LINDNER, Elisabeth ,  COWLEY, Helena ,  COWLEY, Aaron

IPC: A61K38/00 ,  A61K35/74 ,  A61P3/00 ,  A61P3/10

CPC classification number: C07K14/195 ,  A61K35/74 ,  A61K38/00 ,  A61K38/164 ,  C12N9/0006 ,  C12N9/0016 ,  C12N9/0051 ,  C12N9/1014 ,  C12N9/1085 ,  C12N9/14 ,  C12N9/88 ,  C12Y101/0106 ,  C12Y104/01016 ,  C12Y108/01 ,  C12Y201/02001 ,  C12Y205/01006 ,  C12Y205/01009 ,  C12Y205/01047 ,  C12Y303/01001 ,  C12Y402/01003

Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

Abstract translation: 本发明涉及一种衍生自草酸降解细菌的促分泌素化合物，用于治疗受试者中草酸盐相关疾病和/或草酸盐相关的不平衡，其中所述促分泌素的施用导致尿草酸盐和/或 受试者血浆草酸盐。 本发明还涉及包含这种促分泌素化合物的药物组合物，用于治疗患有草酸盐相关疾病的受试者的方法和一种制备促分泌素的方法。

公开(公告)号：WO2016120326A1

公开(公告)日：2016-08-04

申请号：PCT/EP2016/051701

申请日：2016-01-27

Applicant: DANMARKS TEKNISKE UNIVERSITET

Inventor： MUNDHADA, Hemanshu ,  NIELSEN, Alex Toftgaard

IPC: C12P13/06 ,  C12N15/00

CPC classification number: C12N1/36 ,  C07K14/245 ,  C07K14/32 ,  C12N9/0006 ,  C12N9/1014 ,  C12N9/1096 ,  C12N9/1205 ,  C12N9/1217 ,  C12N9/1247 ,  C12N9/16 ,  C12N9/88 ,  C12N9/90 ,  C12N9/93 ,  C12N15/01 ,  C12N15/52 ,  C12P13/001 ,  C12P13/06 ,  C12P13/12 ,  C12P13/22 ,  C12P17/165 ,  C12P17/167 ,  C12Y101/01003 ,  C12Y101/01095 ,  C12Y201/02001 ,  C12Y206/01052 ,  C12Y207/02003 ,  C12Y301/03003 ,  C12Y403/01017

Abstract: The present invention generally relates to the microbiological industry, and specifically to the production of L-serine using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.

Abstract translation: 本发明一般涉及微生物工业，特别涉及使用转基因细菌生产L-丝氨酸。 本发明提供了遗传修饰的微生物，例如细菌，其中编码参与L-丝氨酸降解的酶的基因的表达被减弱，例如通过失活，这使得它们特别适用于在较高的L-丝氨酸生产中 产量。 本发明还提供了使微生物，特别是细菌可以制备成更高浓度丝氨酸的耐受性的方法。 本发明还提供使用这种转基因微生物生产L-丝氨酸或L-丝氨酸衍生物的方法。